CIA
PRME icon

Concurrent Investment Advisors’s Prime Medicine PRME Stock Holding History

Concurrent Investment Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$486K Buy
131,722
+57,545
+78% +$191K ﹤0.01% 1419
2026
Q1 		$258K Buy
+74,177
New +$282K ﹤0.01% 1594

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ACM
Alessandra Capital Management Torrance, California $141M AUM
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return

Concurrent Investment Advisors's PRME Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Prime Medicine (PRME) stake by 78% in Q2 2026, buying an estimated $191K and bringing the position to 131,722 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #1419.

Concurrent Investment Advisors first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Concurrent Investment Advisors held 131,722 shares of Prime Medicine worth $486K as of Q2 2026.
  • Concurrent Investment Advisors bought 57,545 Prime Medicine shares in Q2 2026, an estimated $191K.
  • Prime Medicine made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1419 holding.
  • Concurrent Investment Advisors first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.